GEO series
Transcriptome-based classification of resected pancreatic ductal adenocarcinoma enhances prognostic modelling accuracy of overall survival following adjuvant treatment
GSE310252
Homo sapiens
Expression profiling by high throughput sequencing
118 samples
2026/04/14
GPL24676
Summary
In pancreatic ductal adenocarcinoma, patient outcomes after resection remain highly variable. Prognostic models are often inaccurate. Our study aimed to improve survival prediction by adding transcriptome-based classification to a validated prognostic model and applying it on a multicenter real-world cohort. Fresh-frozen tumor resection materials were obtained from the Dutch Pancreas Parel biobank. RNA was sequenced if tumor cellularity was >30%. The samples were classified using transcriptome-based classification. Survival differences between transcriptome-based subtypes were studied in patients treated with and without adjuvant chemotherapy. Both patients receiving neoadjuvant treatment (NAT) and patients undergoing immediate surgery were included. Samples of 461 patients were collected, of which 118 samples underwent RNA sequencing. Of those, 39.0% were of the basal-like subtype and 61.0% were of the classical subtype. The basal-like subtype became dominant after NAT (63.3%, p = 0.004). Adjuvant gemcitabine-treated patients with a classical tumor survived longer than those with a basal-like tumor (median overall survival (OS): 22.8 vs. 11.4 months; p < 0.001). In multivariable Cox regression, the classical subtype significantly associated with increased survival (hazard ratio = 0.38; p = 0.002) and adding transcriptome-based subtyping significantly improved the prognostic model (p = 0.002). Subtype and adjuvant treatment independently statistically significantly associated with OS. Transcriptome-based subtyping significantly adds to clinical variables in survival prediction after surgery. The independent associations for subtype and adjuvant treatment with OS indicate that subtypes are prognostic, but not predictive for OS with adjuvant treatment. The provided prognostic information could potentially support treatment decisions and serve as stratification factor.
Download
NCBI GEO page ↗
{# Names what the click gives you. "Open in finder" meant nothing to a
visitor who arrived from a search engine and has never seen the tool. #}
Find more
human RNA-seq datasets →
Similar datasets
- GSE328275 Single-cell RNA sequencing of CD45+ immune cells across primary tumor, sentinel tumor-draining lymph node, and axillary lymph node in treatment-naive triple-negative breast cancer 28 samples
- GSE341753 Cohesin loading at regulatory elements shapes 3D genome folding during erythropoiesis [RNA-Seq] 12 samples
- GSE319969 Spatial and Bulk Transcriptomic Profiling Defines the Molecular Evolution of Cutaneous Squamous Cell Carcinoma and Reveals Stage-Specific Biomarkers of Clinical Relevance [RNA-Seq] 24 samples
- GSE342462 Integrated transcriptomic and bioelectrical profiling of stem-like cellular states in a colorectal cancer using SdFFF and UHF-DEP 12 samples
- GSE313035 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin 67 samples
- GSE341139 A conserved HAND2-BMP5-SMAD1/5/9 axis drives hepatic stellate cell activation and extracellular matrix overproduction in multiple fibrotic etiologies 10 samples
- GSE274275 Effect of depletion of NSUN4 on gene expression of NCI-H226 cells [RNA-seq] 6 samples
- GSE330029 Temporal changes in metabolism guide oligodendrocyte precursor cell dynamics in aging and multiple sclerosis [BulkRNAseq] 108 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.